

Serplulimab ASTRUM-005

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



QoL data pending



**Serious and disabling adverse effects**



**Other adjustments**



Serplulimab ASTRUM-005

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Thoracic Malignancies

Therapeutic Indication: Serplulimab in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Experimental Arm: Serplulimab + Carboplatin + Etoposide

Control Arm: Placebo + Carboplatin + Etoposide



